Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial
Launched by RENMIN HOSPITAL OF WUHAN UNIVERSITY ยท
Trial Information
Current as of November 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment option for people with a specific type of bladder cancer called muscle-invasive bladder cancer (MIBC) that tests positive for a protein called HER2. The trial is testing how well a combination of two medicines, disitamab vedotin and toripalimab, works to treat the cancer while keeping the bladder intact, meaning the bladder does not need to be removed. Researchers want to see how effective this treatment is over one year and whether it is safe for patients.
The trial is open to adults aged 65 to 74 with this type of bladder cancer, regardless of gender. If you join the study, you can expect to receive the combination treatment for a certain period and be monitored closely to check how well the treatment is working and to watch for any side effects. This study is still in the early stages and not yet recruiting participants, but it could offer a bladder-preserving option for those with HER2-positive muscle-invasive bladder cancer in the future.
Gender
ALL
Eligibility criteria
About Renmin Hospital Of Wuhan University
Renmin Hospital of Wuhan University is a leading healthcare institution in China, renowned for its commitment to advancing medical research and clinical innovation. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in various medical fields to facilitate cutting-edge studies aimed at improving patient outcomes and healthcare practices. With a strong emphasis on ethical standards and patient safety, Renmin Hospital collaborates with various stakeholders to drive forward-thinking research initiatives that contribute to the global medical community. Its state-of-the-art facilities and multidisciplinary teams enable efficient trial execution, ensuring robust data collection and analysis in pursuit of transformative healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported